BILLIONS of MSCa and AUTOLOGOUS EXOSOMES
Tissue regeneration for horses: the new frontier in veterinary care
Athlete horses face daily stress, micro-trauma and inflammation that can compromise tendons, joints and performance.
With MilliExo Vet®, a new veterinary regenerative medicine solution is born — based on the use of equine adipose tissue as a natural source of mesenchymal stem cells (ADSCs) and high-regenerative-potential exosomes.
An autologous, safe and natural system that combines the scientific research of Dual Trend with the clinical needs of equine sports-veterinary medicine.
The new era of REGENERATIVE
MEDICINE with EXOSOMES
Autologous adipose-tissue harvest
The veterinarian performs a small subcutaneous adipose-tissue harvest, a source rich in mesenchymal stem cells (ADSCs) and natural growth factors.
This autologous approach reduces the risk of rejection and ensures maximum biocompatibility.
Selective micro-filtration
The MilliExo Vet® kit fragments and filters the adipose tissue through calibrated filters, removing fibrous and inflammatory components and preserving the most vital cells (CD44⁺, CD90⁺, CD73⁺).
A homogeneous, sterile micro-filtrate is obtained, ready for activation.
Controlled exosomal activation
In the MilliExo Vet Lab® device, the ideal physiological conditions are reproduced — hypoxia and ≈ 37 °C — which stimulate the ADSCs to release functional exosomes.
These micro-vesicles carry miRNA, proteins and pro-regenerative factors capable of promoting tissue repair in horses, reducing inflammation and speeding up healing.
EQUINE EXOSOMES
The advantages of MilliExo Vet®
- Autologous and biocompatible system – uses exclusively the horse's own tissue
- Rapid and sterile protocol – harvest, preparation and application in the same act
- No enzymes or additives – completely biocompatible and safe method
- Standardised and repeatable – ideal for veterinary clinics and equine sports centres
- Concrete clinical results – reduction of inflammation, tendon and joint regeneration
Clinical applications in equine veterinary medicine
Equine veterinary orthopaedics
-Tendon and ligament injuries
-Arthropathies and cartilage degeneration
-Post-surgical and post-trauma support
Equine sports medicine
- Rapid functional recovery
- Reduction of downtime
- Improved performance and mobility
Well-being and longevity
-Prevention of overload damage
-Physiological tissue regeneration
-Better quality of life for the athlete horse
CONGRESS REPORT – SIVE 2026
by the 4th Mounted Carabinieri Regiment – Delle Medical Center
Frequently Asked Questions about MilliExo Vet®
What is MilliExo Vet®?
MilliExo Vet® is a regenerative veterinary system for equine applications based on the exosomal activation of the horse’s autologous adipose tissue. Through a controlled process under hypoxic conditions and physiological temperature (≈37°C), the adipose microfiltrate releases regenerative exosomes naturally produced by mesenchymal cells. The result is a biological suspension rich in pro-regenerative signals, intended for the repair of equine musculoskeletal tissues.
In which veterinary fields can MilliExo Vet® be used?
MilliExo Vet® is used in equine orthopaedics and sports medicine to support the regeneration of tendons, ligaments, cartilage and joint tissues. It is also indicated for regenerative support in cutaneous lesions, chronic inflammatory conditions and post-trauma recovery in sport and riding horses.
What is the difference between MilliExo Vet® and other regenerative therapies?
Unlike PRP, adipose tissue or traditional cellular suspensions, MilliExo Vet® is based on exosomes naturally released by equine ADSCs. Exosomes contain microRNA, angiogenic factors and reparative molecules that modulate inflammation and stimulate regeneration. It is a biological, autologous, non-cultured and centrifuge-free solution with high purity and safety.
What are the clinical benefits of MilliExo Vet®?
Scientific studies on ADSCs and their exosomes in horses indicate:
- reduction of tendon and joint inflammation
- improved repair of collagen fibres and extracellular matrix
- faster functional recovery in locomotor injuries
- enhanced angiogenesis and tissue oxygenation
Its autologous nature ensures safety and biocompatibility.
Is the MilliExo Vet® procedure invasive?
No. The protocol involves a minimally invasive and sterile adipose extraction, followed by filtration and activation within the dedicated kit. It does not require centrifuges, cell cultures or external laboratories. The entire process is rapid, clean and completely autologous.
How long does the MilliExo Vet® procedure take?
The complete protocol — harvesting, filtration, exosomal activation and application — generally takes around 45 minutes, depending on adipose volume and the treatment area. It must be performed by qualified veterinary specialists.
Are there scientific studies on the regenerative efficacy of equine ADSC exosomes?
Yes. Peer-reviewed publications confirm that exosomes derived from equine adipose-derived mesenchymal cells support tendon regeneration, cartilage repair and inflammatory modulation. Documented outcomes include: structural improvement, reduced inflammation and biomechanical recovery in equine locomotor injuries.
Can MilliExo Vet® be combined with other therapies?
Yes. MilliExo Vet® can be combined with PRP, regenerative physiotherapy, post-injury protocols and equine orthopaedic surgery. The combination can enhance functional recovery and shorten athletic rehabilitation times.
How can I obtain more information about MilliExo Vet®?
It is possible to contact Dual Trend for:
- technical information
- scientific documentation
- practical demonstrations
- veterinary training
Scientific Bibliography — MilliExo Vet® Selected scientific references on adipose-derived stem cells, extracellular vesicles and veterinary regenerative medicine
Dedicated scientific bibliography supporting the biological rationale of adipose-derived regenerative approaches, mesenchymal stromal cells and extracellular vesicles in veterinary and translational medicine.
- Adipose-Derived Stem Cells in Veterinary Medicine: Characterization and Therapeutic Applications Stem Cells and Development, 2015. PMID: 25556829 — PubMed
-
Intraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell- and Tissue-Based Therapies: Concise Review
Stem Cells Translational Medicine, 2019.
PMCID: PMC6877766
PMID: 31599497 — PubMed -
Minimal Information for Studies of Extracellular Vesicles — MISEV2023: From Basic to Advanced Approaches
Journal of Extracellular Vesicles, 2024.
PMCID: PMC10850029
PMID: 38326288 — PubMed - Emerging Role of Extracellular Vesicles in Veterinary Practice: Novel Opportunities and Potential Challenges Frontiers in Veterinary Science, 2024. PMID: 38332755 — PubMed
-
Exosome Secretion Kinetics Are Controlled by Temperature
Biophysical Journal, 2023.
PMCID: PMC10111348
PMID: 36814381 — PubMed -
Regenerative Medicine for Equine Musculoskeletal Diseases
Animals, 2021.
PMCID: PMC7832834
PMID: 33477808 — PubMed - Stem Cells and Platelet-Rich Plasma for the Treatment of Naturally Occurring Equine Tendon and Ligament Injuries: A Systematic Review and Meta-Analysis Journal of the American Veterinary Medical Association, 2024. PMID: 38471305 — PubMed
-
Mesenchymal Stem Cell Therapy in Canine Osteoarthritis Research: “Experientia Docet” — Experience Will Teach Us
Frontiers in Veterinary Science, 2021.
PMCID: PMC8169969
PMID: 34095280 — PubMed - Mesenchymal Stromal Cell Therapy for Feline Chronic Gingivostomatitis: Long-Term Experience Frontiers in Veterinary Science, 2023. PMID: 37168097 — PubMed
-
Current Advances in Mesenchymal Stem Cell Therapies Applied to Wounds and Skin, Eye, and Neuromuscular Diseases in Companion Animals
Animals, 2024.
PMCID: PMC11083242
PMID: 38731367 — PubMed - Mesenchymal Stem Cell Therapy in Veterinary Ophthalmology: Clinical Evidence and Prospects Veterinary Research Communications, 2024. PMID: 39212813 — PubMed
-
The Functions and Clinical Application Potential of Exosomes Derived from Adipose Mesenchymal Stem Cells
Stem Cells Translational Medicine, 2019.
PMCID: PMC6686455
PMID: 31391108 — PubMed -
Therapeutic Application of Extracellular Vesicles Derived from Mesenchymal Stem Cells in Domestic Animals
Animals, 2024.
PMCID: PMC11310970
PMID: 39123673 — PubMed - Efficacy of Mesenchymal Stem Cell Therapy for Treating Deep Corneal Ulcers and Corneal Perforation in Cats: A Retrospective Study Journal of Feline Medicine and Surgery, 2026. DOI: 10.1177/1098612X261423236 — SAGE / DOI